BioHealth News
TEDCO Announces Federal Lab Leveraging Innovation to Products Pilot Program
Senators Cardin and Van Hollen requested more than $1 million to fund this new program COLUMBIA, Md., (April 11, 2024) — TEDCO, Maryland’s economic engine…
Read More
TEDCO Invests in Aloe Therapeutics
COLUMBIA, Md. (April 8, 2024) – TEDCO, Maryland’s economic engine for technology companies, announced a recent $100,000 Pre-Seed Builder Fund investment in Aloe Therapeutics,…
Read More
Technical.ly: How Baltimore plans to spend $70M in EDA Tech Hubs Funding
Anticipation is building for the pending decision on Baltimore’s Phase 2 Tech Hubs application to the US Economic Development Administration (EDA). That energy was…
Read More
Medcura Closes $22.4 Million Financing to Accelerate Development of Surgical Hemostatic Gel and Surgical Hemostasis Portfolio
RIVERDALE, Md., April 3, 2024 /PRNewswire/ -- Medcura, Inc., a developer of hemostatic products for use in surgery, today announced that it has closed a private placement…
Read More
NeoImmuneTech Appoints Dr. Luke Oh, Ph.D. as New Chief Executive Officer
ROCKVILLE, Md., April 2, 2024 /PRNewswire/ -- NeoImmuneTech, Inc. (KOSDAQ: 950220), announced that Luke Oh, Ph.D. has been appointed as President and Chief Executive Officer (CEO)…
Read More
CF Foundation Provides Up to $8.5M to SpliSense to Support a Clinical Trial for a Potential Treatment for Splicing Mutations
BETHESDA, Md.--(BUSINESS WIRE)--The Cystic Fibrosis Foundation is investing up to $8.5 million in additional funds in SpliSense to continue clinical trials for its inhaled antisense…
Read More
Washington DC’s Vanda Pharmaceuticals’ Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
WASHINGTON, April 2, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved Fanapt® (iloperidone) tablets for…
Read More
Washington D.C.’s 60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
WASHINGTON, April 03, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (or the “Company”), a pharmaceutical company focused on developing new medicines for infectious…
Read More
Kemp Proteins and Columbia Biosciences Announce Strategic Partnership for Fluorophore Conjugation Solutions
April 2, 2024, Frederick, Maryland — Kemp Proteins LLC, a leading provider of monoclonal antibody development and gene-to-protein services, announced today that the company…
Read More
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programsROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE)…
Read More
Major investments in Maryland’s life sciences sector
Investment in Maryland’s life sciences community is heating up only a few months into 2024. From new market launches to expanded production capabilities to…
Read More
TEDCO Invests in Baltimore Medical Device Company LASARRUS
COLUMBIA, Md. (April 1, 2024) – TEDCO, Maryland’s economic engine for technology companies, announced a recent $50,000 Pre-Seed Builder Fund investment in LASARRUS, a…
Read More
Maryland Life Science Trend Analysis 2024
Venture financing for Maryland’s life sciences industry in 2023 shows signs of recovery following the significant downturn in 2022, with the total value of…
Read More
Baltimore’s LaunchPort Welcomes New Resident JuneBrain
LaunchPort welcomes CEO Samantha Scott and her team as the latest Residents to join the Baltimore Peninsula site. JuneBrain Inc. (https://www.junebrain.com/) offers accessible monitoring…
Read More
BioBuzz Networks and the International Society of Pharmaceutical Engineering – Chesapeake Bay Area Chapter Announce Exciting Partnership
March 28, 2024, Baltimore, MD. – BioBuzz Networks and the International Society of Pharmaceutical Engineering (ISPE) – Chesapeake Bay Area (CBA) Chapter are pleased to…
Read More